APGE Stock Summary and Trading Ideas (Apogee Therapeutics | NASDAQ:APGE)

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Apogee Therapeutics trades on the NASDAQ stock market under the symbol APGE.

As of March 5, 2026, APGE stock price declined to $70.92 with 1,077,031 million shares trading.

APGE has a beta of 0.91, meaning it tends to be less sensitive to market movements. APGE has a correlation of 0.06 to the broad based SPY ETF.

APGE has a market cap of $4.85 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that APGE belongs to (by Net Assets): VTI, IWM, XBI, VXF, TCAF.

APGE has outperformed the market in the last year with a price return of +133.5% while the SPY ETF gained +19.4%. However, in the short term, APGE had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.1% vs -0.2% return in SPY. But in the last 2 weeks, APGE shares have fared better than the market returning +0.9% compared to SPY -0.7%.

APGE support price is $69.57 and resistance is $75.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APGE shares will trade within this expected range on the day.